Merck & Co. Inc.'s Keytruda (pembrolizumab) continued to shine in non-small cell lung cancer (NSCLC) in data presented at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark. The anti-programmed cell death protein 1 (PD-1) therapy showed superior overall survival (OS) at 18 months compared to docetaxel in patients with metastatic NSCLC previously treated with platinum-containing chemotherapy whose tumors expressed programmed death ligand 1 (PD-L1) – measured as tumor proportion score (TPS) of 1 percent or more – as well as those with high levels of PD-L1 expression (TPS of 50 percent or more).